Movement Disorders (revue) - Curation (PubMed)

Index « MedMesh.i » - entrée « Dose-Response Relationship, Drug »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Dopaminergic Neurons < Dose-Response Relationship, Drug < Dose-Response Relationship, Immunologic  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 332.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000443 (2014) Rupam Borgohain [Inde] ; Jozsef Szasz ; Paolo Stanzione ; Chandrashekhar Meshram ; Mohit H. Bhatt ; Dana Chirilineau ; Fabrizio Stocchi ; Valentina Lucini ; Rodolfo Giuliani ; Emma Forrest ; Patricia Rice ; Ravi AnandTwo-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
000491 (2014) Erwan Bezard [République populaire de Chine] ; Elsa Y. Pioli ; Qin Li ; Françoise Girard ; Vincent Mutel ; Charlotte Keywood ; Francois Tison ; Olivier Rascol ; Sonia M. PoliThe mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
000559 (2014) Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. FacherisCombined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
000661 (2014) Rupam Borgohain [Inde] ; J. Szasz ; P. Stanzione ; C. Meshram ; M. Bhatt ; D. Chirilineau ; F. Stocchi ; V. Lucini ; R. Giuliani ; E. Forrest ; P. Rice ; R. AnandRandomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
000742 (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
000838 (2013) Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destee ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000931 (2013) C. Warren Olanow [États-Unis] ; Karl Kieburtz ; Olivier Rascol ; Werner Poewe ; Anthony H. Schapira ; Murat Emre ; Helena Nissinen ; Mika Leinonen ; Fabrizio StocchiFactors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
000940 (2013) Stewart A. Factor [États-Unis] ; Kenneth Wolski ; Daniel M. Togasaki ; Susan Huyck ; Marc Cantillon ; T W Ho ; Robert A. Hauser ; Emmanuelle PourcherLong-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.
000978 (2013) Serge H. Roy [États-Unis] ; Bryan T. Cole ; L Don Gilmore ; Carlo J. De Luca ; Cathi A. Thomas ; Marie M. Saint-Hilaire ; S Hamid NawabHigh-resolution tracking of motor disorders in Parkinson's disease during unconstrained activity.
000994 (2013) Yoshikuni Mizuno [Japon] ; Tomoyoshi KondoAdenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
000A09 (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
000A78 (2013) Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins ; Kathryn A. Chung ; Robert A. Hauser ; Janis M. Miyasaki ; Anthony P. Nicholas ; Werner Poewe ; Klaus Seppi ; Olivier Rascol ; Mark A. Stacy ; John G. Nutt ; Caroline M. Tanner ; Alison Urkowitz ; Jean A. Jaglin ; Song GeWhich dyskinesia scale best detects treatment response?
000B02 (2013) Anne-Marie A. Wills [États-Unis] ; Shirley Eberly ; Marsha Tennis ; Anthony E. Lang ; Susan Messing ; Daniel Togasaki ; Caroline M. Tanner ; Cornelia Kamp ; Jiang-Fan Chen ; David Oakes ; Michael P. Mcdermott ; Michael A. SchwarzschildCaffeine consumption and risk of dyskinesia in CALM-PD.
000C72 (2012) Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. MolineDonepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
000D17 (2012) Donald L. Bliwise [États-Unis] ; Lynn Marie Trotti ; Anthony G. Wilson ; Sophia A. Greer ; Cathy Wood-Siverio ; Jorge J. Juncos ; Stewart A. Factor ; Alan Freeman ; David B. RyeDaytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.
000D99 (2012) Lissa S. Brod [États-Unis] ; Jason L. Aldred ; John G. NuttAre high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
000E36 (2012) Caterina Mariotti [Italie] ; Roberto Fancellu ; Serena Caldarazzo ; Lorenzo Nanetti ; Daniela Di Bella ; Massimo Plumari ; Giuseppe Lauria ; Maria D. Cappellini ; Lorena Duca ; Alessandra Solari ; Franco TaroniErythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
000F47 (2012) Andrew Lees [Royaume-Uni] ; Stanley Fahn ; Karla M. Eggert ; Joseph Jankovic ; Anthony Lang ; Federico Micheli ; M Maral Mouradian ; Wolfgang H. Oertel ; C Warren Olanow ; Werner Poewe ; Olivier Rascol ; Eduardo Tolosa ; David Squillacote ; Dinesh KumarPerampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.
001035 (2011) Robert D. Altman [Canada] ; Anthony E. Lang ; Ronald B. PostumaCaffeine in Parkinson's disease: a pilot open-label, dose-escalation study.
001056 (2012) Fabrizio Stocchi [Italie] ; Rupam Borgohain ; Marco Onofrj ; Anthony H V. Schapira ; Mohit Bhatt ; Valentina Lucini ; Rodolfo Giuliani ; Ravi AnandA randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
001061 (2012) Robert Chinnapongse [États-Unis] ; Kristen Gullo ; Paul Nemeth ; Yuxin Zhang ; Lynn GriggsSafety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i -k "Dose-Response Relationship, Drug" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/MedMesh.i  \
                -Sk "Dose-Response Relationship, Drug" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Dose-Response Relationship, Drug
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024